https://www.selleckchem.com/pr....oducts/gsk2606414.ht
e of hospitalizations by 20% using MR-proADM. The safety in the MR-proADM guided study arm was similar to the Standard Care arm. ClinicalTrials.gov Identifier NCT03770533. ClinicalTrials.gov Identifier NCT03770533.The aim of this prospective study was to report the experience with a specific guided distraction protocol for the treatment of CLP patients with severe midface hypoplasia. From January 2016 to April 2019, six consecutive, non-growing, CLP patients with maxillary hypoplasia underwent a specific distraction protocol based on
Beğen
Yorum Yap
Paylaş
